Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 19,594 shares, a drop of 54.7% from the December 31st total of 43,229 shares. Currently, 3.2% of the shares of the company are short sold. Based on an average daily volume of 107,054 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 107,054 shares, the short-interest ratio is presently 0.2 days. Currently, 3.2% of the shares of the company are short sold.

Biodexa Pharmaceuticals Stock Down 3.7%

Shares of Biodexa Pharmaceuticals stock opened at $2.08 on Thursday. The business has a 50-day simple moving average of $3.54 and a 200 day simple moving average of $5.68. Biodexa Pharmaceuticals has a one year low of $2.00 and a one year high of $92.00.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BDRX shares. Wall Street Zen raised Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.